Lucosky Brookman LLP Represents Titan Partners Group as Sole Placement Agent in $15 Million Registered Direct Offering for Belite Bio
Lucosky Brookman LLP represented Titan Partners Group, a division of American Capital Partners, as sole placement agent in a $15 million registered direct offering for Belite Bio, Inc. (Nasdaq: BLTE), a clinical-stage biotech company focused on advancing novel therapeutics targeting degenerative retinal diseases with significant unmet medical needs.
The offering consisted of the sale of 230,770 American Depositary Shares (ADSs) and warrants to purchase an equal number of ADSs, at a purchase price of $65 per ADS and accompanying warrant. The transaction was completed with a single large existing institutional shareholder and is expected to generate gross proceeds of approximately $15 million, with potential for an additional $15 million from the exercise of five-year warrants.
Belite Bio intends to use the net proceeds from the offering for working capital and general corporate purposes to support the continued development of its pipeline targeting conditions such as Stargardt disease and Geographic Atrophy in advanced dry age-related macular degeneration.
This transaction highlights strong investor confidence in Belite Bio’s mission to develop transformative treatments for retinal degenerative diseases and positions the company to advance its clinical programs with enhanced financial resources.